Granite Bio (Series A and Series B)

Funding Details
Awarder
Inbox
Date Award
April 25, 2025
Vertical
Biotechnology
Funding URL
View Funding Page

Company Info
Traction
Granite Bio has secured $100 million in funding, indicating strong investor confidence and market potential for its antibody treatments.
Company Description
Granite Bio is a Swiss-based immunology company focused on developing new antibody treatments targeting various autoimmune diseases. The company aims to address fundamental disease drivers at their source with innovative therapies.
Market
Immunology
Location
Switzerland
Coinvestors
Versant Ventures, Novartis Venture Fund, Sanofi Ventures, Forbion

Links
Back to Home Back to Biotechnology Deals View Funding Announcement